Amneal Pharmaceuticals, Inc. (AMRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Amneal Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Amneal Pharmaceuticals, Inc. (AMRX) has returned -1.35% so far this year and 48.33% over the past 12 months. Over the last ten years, AMRX has returned -9.37% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jan 15, 2009, AMRX's average daily return is +0.09%, while the average monthly return is +1.50%. At this rate, your investment would double in approximately 3.9 years.

Historically, 53% of months were positive and 47% were negative. The best month was Dec 2023 with a return of +40.8%, while the worst month was Jul 2019 at -49.0%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.

On a daily basis, AMRX closed higher 49% of trading days. The best single day was Feb 20, 2009 with a return of +47.7%, while the worst single day was Jul 10, 2019 at -36.0%.

Amneal Pharmaceuticals, Inc. has an annualized alpha of 8.57%, beta of 1.05, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since January 16, 2009.

• This stock participated in 158.25% of S&P 500 Index downside but only 129.55% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AMRX ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Amneal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amneal Pharmaceuticals, Inc. was 97.52%, occurring on Mar 28, 2023. The portfolio has not yet recovered.

The current Amneal Pharmaceuticals, Inc. drawdown is 75.77%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Amneal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Amneal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.